Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study
BEDMINSTER, N.J. and DUBLIN, Ireland, March 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced …